Literature DB >> 16048546

Involvement of intestinal dendritic cells in oral tolerance, immunity to pathogens, and inflammatory bowel disease.

Brian L Kelsall1, Francisco Leon.   

Abstract

Dendritic cells (DCs) are composed of a family of cells, now recognized to be essential for innate and acquired immunity. DCs at mucosal surfaces have a particular capacity to induce the differentiation of regulatory T cells producing interleukin-10 (IL-10) and transforming growth factor-beta (TGF-beta) in the steady state (non-infected, non-immunized), yet they retain the capacity to induce effector T cells in response to invasive pathogens. This decision between the induction of active immunity and tolerance will depend on the subpopulation of DC involved and the surface receptors engaged during DC activation and T-cell priming. The local microenvironment will likely play an important role both in defining the DC phenotype and in providing direct signals to responding T cells. Furthermore, DCs in organized mucosal lymphoid tissues preferentially induce the expression of CCR9 and alpha4beta7 on T cells, which results in T-cell homing to the intestinal lamina propria. Finally, DCs may play an important role in the maintenance of abnormal intestinal inflammation either by driving pathogenic T-cell responses in mesenteric lymph nodes or by acting to expand or maintain pathogenic T cells locally at sites of inflammation. In this review, a brief discussion of general issues of DC biology that are pertinent to mucosal immunity is followed by a more in-depth discussion of the phenotype and function of DC populations in the intestine.

Entities:  

Mesh:

Year:  2005        PMID: 16048546     DOI: 10.1111/j.0105-2896.2005.00292.x

Source DB:  PubMed          Journal:  Immunol Rev        ISSN: 0105-2896            Impact factor:   12.988


  55 in total

1.  Oral administration of Alequel, a mixture of autologous colon-extracted proteins for the treatment of Crohn's disease.

Authors:  Eran Israeli; Yaron Ilan
Journal:  Therap Adv Gastroenterol       Date:  2010-01       Impact factor: 4.409

Review 2.  Immunopathogenesis of IBD: insufficient suppressor function in the gut?

Authors:  I L Huibregtse; A U van Lent; S J H van Deventer
Journal:  Gut       Date:  2006-10-17       Impact factor: 23.059

Review 3.  Inflammatory bowel disease, past, present and future: lessons from animal models.

Authors:  Atsushi Mizoguchi; Emiko Mizoguchi
Journal:  J Gastroenterol       Date:  2008-02-24       Impact factor: 7.527

Review 4.  Probiotics and prebiotics in inflammatory bowel disease: microflora 'on the scope'.

Authors:  Dimitrios Damaskos; George Kolios
Journal:  Br J Clin Pharmacol       Date:  2008-02-12       Impact factor: 4.335

Review 5.  Immune and non-immune functions of the (not so) neonatal Fc receptor, FcRn.

Authors:  Kristi Baker; Shuo-Wang Qiao; Timothy Kuo; Kanna Kobayashi; Masaru Yoshida; Wayne I Lencer; Richard S Blumberg
Journal:  Semin Immunopathol       Date:  2009-06-03       Impact factor: 9.623

Review 6.  Mononuclear phagocyte diversity in the intestine.

Authors:  Milena Bogunovic; Arthur Mortha; Paul Andrew Muller; Miriam Merad
Journal:  Immunol Res       Date:  2012-12       Impact factor: 2.829

7.  Tumour necrosis factor alpha contributes to protection against Giardia lamblia infection in mice.

Authors:  P Zhou; E Li; T Shea-Donohue; S M Singer
Journal:  Parasite Immunol       Date:  2007-07       Impact factor: 2.280

Review 8.  New thoughts on the pathobiology of regimen-related mucosal injury.

Authors:  Lowell Anthony; Joanne Bowen; Adam Garden; Ian Hewson; Stephen Sonis
Journal:  Support Care Cancer       Date:  2006-04-01       Impact factor: 3.603

Review 9.  Recent progress in understanding the phenotype and function of intestinal dendritic cells and macrophages.

Authors:  B Kelsall
Journal:  Mucosal Immunol       Date:  2008-09-17       Impact factor: 7.313

Review 10.  Cross-presentation of IgG-containing immune complexes.

Authors:  Kristi Baker; Timo Rath; Wayne I Lencer; Edda Fiebiger; Richard S Blumberg
Journal:  Cell Mol Life Sci       Date:  2012-07-31       Impact factor: 9.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.